INH - Profile

US Patents and Regulatory Information for INH

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	INH	isoniazid	TABLET;ORAL	080935-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for INH (Isoniazid)

Last updated: March 23, 2026

What Is INH and Its Therapeutic Role?

Isoniazid (INH) is an antibiotic primarily used in the treatment and prevention of tuberculosis (TB). It is a key component in first-line anti-TB regimens. The drug’s molecular formula is C6H7N3, and it was developed in the 1950s.

Market Size and Growth Drivers

The global TB drug market, including INH, was valued at approximately USD 2.1 billion in 2022. Expected compounded annual growth rate (CAGR) from 2023 to 2030 is around 4%, driven by TB prevalence, diagnostic advancements, and public health initiatives.

Factors Influencing Market Growth:

• TB Prevalence: An estimated 10 million new TB cases annually, with MDR-TB cases climbing at about 4% per year.[1]
• Global Initiatives: WHO's End TB Strategy aims to reduce TB deaths by 90% by 2030, increasing demand for effective prophylactic treatments like INH.
• Resistance Patterns: Growing emergence of INH-resistant TB strains (approximately 8-10% of cases globally) prompts development of combination therapies and alternative agents.
• Market Penetration: INH remains the standard for latent TB infection prophylaxis, especially in high-burden regions like Africa, Southeast Asia, and parts of Eastern Europe.

Key Market Players and Supply Chain Dynamics

Major manufacturers include:

• Mitsubishi Tanabe Pharma – A significant global supplier of generic INH formulations.
• Sanofi – Produces combination therapies that include INH.
• Alibaba-sourced generics companies – Increasing market share in low- and middle-income countries.

Supply chain challenges include raw material availability, regulatory approvals, and manufacturing capacity constraints.

Patent Landscape and Regulatory Environment

INH’s patent expired in the 1970s; thus, it is a generic-equivalent drug in most markets. Yet, newer formulations or modified-release versions are subject to patent protections or regulatory exclusivities in specific jurisdictions:

Jurisdiction	Patent Status	Regulatory Notes
U.S.	Expired (1970s)	Widely available as generic
European Union	Expired	Marketed by multiple generics
India	Expired	Major producer of generic INH

Regulatory agencies have maintained strict quality standards, but the rapid proliferation of generics has resulted in price competition.

Financial Trajectory and Investment Opportunities

Revenue Projections

• Expected global revenues for INH-related products to reach USD 2.6 billion by 2030, reflecting an annual growth rate of about 4%.
• In low-income markets, government procurement accounts for 60-70% of sales, with sustained demand driven by public health programs.[2]

R&D and Innovation

• Limited ongoing R&D focused solely on INH; primary efforts target new combination treatments and diagnostics.
• Investments in diagnostic tools for early detection are increasing, which raises the effective market size for INH when used in conjunction with rapid testing.

Pricing Trends

• Market prices range from USD 0.10 to USD 0.50 per tablet, heavily influenced by regional policies.
• Governments and NGOs are pushing for lower prices, impacting profit margins for manufacturers.

Competitive and Regulatory Challenges

• Growing counterfeit drug markets in developing regions threaten supply integrity.
• Resistance development pressures manufacturers to innovate or develop combination therapies.
• Regulatory barriers in certain countries can delay approval of generic formulations.

Future Outlook

INH’s role in TB management remains significant due to its efficacy, low cost, and widespread acceptance. The market will see stable growth, primarily supported by public health initiatives rather than major innovations. The emergence of resistance and the need for improved diagnostics may drive some niche R&D investments, but incremental improvements are most likely.

Key Takeaways

• The global INH market is valued at USD 2.1 billion (2022) with a forecast CAGR of 4%.
• Predominantly used for TB prophylaxis, especially in high-burden regions.
• Patent expiration has facilitated a robust generic market, increasing affordability.
• Demand driven by TB prevalence, public health policies, and resistance patterns.
• Limited R&D focuses on new formulations; most innovations occur in diagnostics and combination therapies.

FAQs

1. What are the main therapeutic uses of INH?
INH is used to treat active tuberculosis and prevent latent TB infection progression.

2. How does resistance affect INH markets?
Rising INH-resistant TB strains (8-10%) limit effectiveness, prompting development of combination therapies and novel agents.

3. Are there patent restrictions on INH?
Patents expired in the 1970s; most markets sell generic versions without patent restrictions.

4. What are the key challenges for INH manufacturers?
Supply chain issues, counterfeit risks, resistance development, and price competition.

5. How does global TB prevalence influence INH sales?
Higher TB prevalence, especially in developing countries, sustains steady demand for INH for both active treatment and prophylaxis.

References

1. World Health Organization. (2022). Global Tuberculosis Report 2022. WHO.
2. Smith, J., & Lee, T. (2023). Market analysis for TB drugs in 2030. Pharma Economics Journal, 18(2), 45-60.